2 completed, 1 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Afimetoran: new trials by email Literature Review of Afimetoran trials Research Report on Afimetoran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus Afimetoran, Placebo - Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus | Phase 2 / Phase 3 | Recruiting | Beeline Medicines Corporation | 390 | 2026-10-01 | 2026-10-29 |
| A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants Famotidine, Afimetoran - Healthy Volunteers | Phase 1 | Completed | Bristol-Myers Squibb | 32 | 2023-07-04 | 2026-05-13 |
| A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam Afimetoran, Phenytoin, Midazolam - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 65 | 2023-06-14 | 2024-08-07 |
| A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) Afimetoran, Placebo - Systemic Lupus Erythematosus | Phase 2 | Active not recruiting | Beeline Medicines Corporation | 248 | 2021-10-11 | 2026-08-17 |
Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Immune System Diseases (1) · Lupus Erythematosus, Cutaneous (1) · Lupus Erythematosus, Discoid (1) · Lupus Erythematosus, Systemic (1)
Beeline Medicines Corporation (2) · Bristol-Myers Squibb (2)
United States (3) · United Kingdom (2) · Argentina (1) · Australia (1) · Brazil (1) · Chile (1) · China (1) · Colombia (1) · France (1) · Germany (1) · India (1) · Ireland (1) · Japan (1) · Mexico (1) · Poland (1)
2023 (1)